A Single-Center, Randomized, Double-Blind, Double-Dummy Placebo Controlled, Cross-Over Study to Investigate the Next Morning Effects of Ramelteon (8mg), Zopiclone (7.5mg) and Placebo on Actual Driving Performance, Memory Functioning, Psychomotor Performance in Adults with Chronic Insomnia
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Ramelteon (Primary) ; Zopiclone (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Takeda
Most Recent Events
- 03 Apr 2022 Status changed from recruiting to completed.
- 07 Oct 2011 Takeda has discontinued the development of ramelteon in Europe for the treatment of insomnia.
- 25 Jul 2011 New trial record